Atrix Atridox
Executive Summary
Atrix has begun manufacturing launch quantities of its periodontal disease treatment Atridox, Atrix Vice Chairman and CEO John Urheim indicates. "Coming Soon" ads, placed by marketing partner Block Drug, are now appearing in dental journals. Block will promote the doxycyline gel with 80 sales reps. The marketing agreement includes $50 mil. in milestone payments and $10 mil. at approval. FDA issued an "approvable" letter April 8; Atrix is discussing labeling with the agency